Jianhua Liang

Director, Institute of New Drug Development and Green Synthesis
Deputy Director of Key Laboratory of Pharmaceutical Molecular Science and Pharmaceutical Engineering
Major: Chemical Engineering and Technology/Pharmaceutical Engineering/Chemistry/Pharmacy
Research interests: Innovative drug development for major diseases

The natural products with physiological activity were studied by chemical and biological means, and the structure-activity relationship, structure-relationship and mechanism of action were elucidated by structural modification, with a view to obtaining preclinical candidate compounds with in vitro and in vivo activity for major disease models.
1) Drug development against drug-resistant bacteria: macrolide antibiotics regulate ribosomal protein output, explore new targets and design multiple targets
2) Antidepressant drug development: Small molecules promote in situ neurogenesis, reshaping brain anti-depression
3) Development of anti-diabetic drugs: Design of glycosidated compounds of glycoside flavones
4) Anti-inflammatory drug development: triterpene natural product modification and glycosidation
5) Synthetic biology: Cell modification to synthesize natural products

1999.9~2004.3 Beijing Institute of Technology, School of Materials Science and Engineering, Doctor (Outstanding graduate of the Commission of Science, Technology and Industry for National Defense)
1995.9~1999.7 College of Chemical Engineering and Materials, Beijing Institute of Technology, Bachelor (Beijing Outstanding Graduate)

2004.4-present Lecturer/Associate Professor/Professor, School of Chemistry and Chemical Engineering, Beijing Institute of Technology
2019.7~2020.8 College of Pharmacy, University of Minnesota, Visiting Professor
2010.4~2011.4 College of Pharmacy, Purdue University, Visiting Professor

Host and participate in projects:
2023.12-2026.12, Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund focused on "Screening and Evaluation of potential treatment drugs for multiple sclerosis based on Mendelian Random Analysis" (L232017)
2022.8-2027.7, Science and Technology Innovation 2030- Brain Science and brain-like Research major project "Research on the Pathogenesis and Intervention Technology of Depression" (2022ZD0211700)
2019.7-2024.6, National Research and Development Key Plan - Synthetic biology special "Microbial cell factory Construction and Application Demonstration of Synthetic Plant Natural Products" (2018YFA0901800)
2019.1-2022.12, National Natural Science Foundation of China Project "Design, Synthesis and Proliferation and Differentiation Mechanism of Neuroregenerative azoflavones" (21878022)
2017.1-2020.12, National Natural Science Foundation of China Project "Design, Synthesis and Bactericidal Mechanism of a novel Drug-resistant bacterium erythromycin with a New antibacterial Mode" (81673335)
From 2017 to 2018, the enterprise horizontal project "Development of glucoside flavonoids, a Class 1 new drug for lowering blood sugar (BIT-ROC-201721641121)
2014-2015, Beijing Outstanding Talents Training Funding Project (Category D) "Design and structure-Activity Relationship of Multi-target Macrolide Antibiotics with bactericidal Properties" (2013D009011000002)
2013-2014, Beijing Institute of Technology Outstanding Young Teachers Funding Program "Research on structure-Activity Relationship of Novel non-ketolactones and Their Resistance to drug-resistant Bacteria Based on a New Binding Model" (2012YG1606)
2014-2014, Frontier and Interdisciplinary Innovation Program of Beijing Institute of Technology "Research on New drugs for Treating Alzheimer's Disease" (2014CX11001)
2007-2009, National Natural Science Foundation of China Youth Project "Design and Synthesis of novel macrolide Antibiotics with antimicrobial activity" (20602002)
Representative Papers:
Researcher ID: http://www.researcherid.com/rid/A-1186-2013
ORCID: https://orcid.org/0000-0003-1309-8521